Shots:
- Piramal Pharma Solutions has entered into a strategic collaboration with Ajinomoto Bio-Pharma Services to support antibody-drug conjugate (ADC) development and manufacturing programs
- Under the agreement, Piramal will refer customers to Ajinomoto’s AJICAP platform for site-specific ADC conjugation, while Ajinomoto will direct clients to Piramal for CDMO manufacturing services across development and commercialization
- The collaboration includes a planned Material Transfer Agreement to enable technology transfer, allowing Piramal to manufacture AJICAP-based ADCs, combining platform innovation with large-scale GMP manufacturing expertise
Ref: PR Newswire | Image: Piramal Pharma Solutions and Ajinomoto Bio-Pharma| Press Release
Related News: Interna Therapeutics Collaborates with Daiichi Sankyo to Develop MNM-Based Targeted Delivery Technologies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
